Patients' preferences for adjuvant endocrine therapy in early breast cancer
Author Information
Author(s): Duric V M, Fallowfield L J, Saunders C, Houghton J, Coates A S, Stockler M R
Primary Institution: NHMRC Clinical Trials Centre, University of Sydney
Hypothesis
What benefits do women require to consider adjuvant endocrine therapy worthwhile?
Conclusion
Many women required larger benefits than expected to consider adjuvant endocrine therapy worthwhile.
Supporting Evidence
- About a third of women judged gains of 1% in survival rate or 6 months in survival time sufficient.
- More than half judged gains of at least 5% or 3 years necessary.
- Women who had tamoxifen judged smaller benefits necessary compared to those who had goserelin.
Takeaway
Women with early breast cancer want to see big improvements in survival to feel that their treatment is worth it.
Methodology
Women were interviewed about their preferences for adjuvant endocrine therapy based on hypothetical survival scenarios.
Potential Biases
Selection bias may affect comparisons between women who did and did not receive tamoxifen.
Limitations
The sample may not represent all women considering adjuvant endocrine therapy, and preferences were based on recollections of treatment experiences.
Participant Demographics
Median age was 45 years; most were married (84%) and had children (88%).
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website